Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19

Fang, Jia-YouJia-YouFangHuang, Kuo-YenKuo-YenHuangWang, Tong-HongTong-HongWangLin, Zih-ChanZih-ChanLinChen, Chin-ChuanChin-ChuanChenSUI-YUAN CHANGChen, En-LiEn-LiChenTAI-LING CHAOYang, Shuenn-ChenShuenn-ChenYangPAN-CHYR YANGChen, Chi-YuanChi-YuanChen2024-04-262024-04-262024-04-121477-3155https://scholars.lib.ntu.edu.tw/handle/123456789/642108Angiotensin-converting enzyme 2 (ACE2) and AXL tyrosine kinase receptor are known to be involved in the SARS-CoV-2 entry of the host cell. Therefore, targeting ACE2 and AXL should be an effective strategy to inhibit virus entry into cells. However, developing agents that can simultaneously target ACE2 and AXL remains a formidable task. The natural compound quercetin has been shown to inhibit AXL expression.enACE2; AXL; COVID-19; Nanoparticles; Quercetin[SDGs]SDG3Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19journal article10.1186/s12951-024-02435-2386099982-s2.0-85190284080https://api.elsevier.com/content/abstract/scopus_id/85190284080